Posted 7th January 2019 by Jane Williams
It was a pleasure to welcome key opinion leaders to a discussion on accelerating the impact of AI through 100% digitization of the pathology workflow. Chaired by Peter Hamilton, Head of Research at Philips Digital & Computational Pathology, barriers to adoption, what drives the need and how do we reap the benefits were all on the agenda.
If you weren’t able to make the panel discussion, this six-part blog series will uncover what was discussed. Alternatively, you can watch the recording here.
Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines
Posted 17th October 2018 by Kieran Chambers
Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.
Posted 28th September 2018 by Kieran Chambers
When we last spoke, Brandon Allgood told us about The Future of AI. This week, we caught up with Brandon and spoke about drug discovery and machine learning algorithms.
Posted 17th September 2018 by Kieran Chambers
Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.
Posted 3rd September 2018 by Kieran Chambers
Brandon Allgood is the Chief Technology Officer at Numerate, as well as a co-founder. In addition to being responsible for the development of Numerate’s cloud-based machine learning platforms, Brandon runs the software & data science teams, and is the technical lead on all of the companies internal drug programs, as well as external collaborations.
Here, Brandon talks about what he thinks the future holds for AI and machine learning:
Posted 28th May 2018 by Anna Gomez
As the field of digital pathology continues to evolve, we are discovering new and exciting ways to use and apply the technology. Digital Pathology is entering a new era, revealing an unprecedented breadth and depth of information for cancer research and diagnosis. Whole slide imaging (WSI) will take an important role in the development of future technologies, imaging modalities and systems, and impact clinical workflows, yielding a comprehensive multi-dimensional analysis that would otherwise be impossible!
Posted 2nd April 2018 by Anna Gomez
An evaluation of the UK’s pathology capacity by Cancer Research UK (CRUK) has identified that over the next 5-10 years “there is likely to be a severe crisis.” The report highlights a 4.5% year-on-year increase in the number and complexity of histopathology requests since 2007/08; the majority of which are for the investigation of cancer.